Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells

A majority of patients with BRAF-mutated metastatic melanoma respond to therapy with BRAF inhibitors (BRAFi), but relapses are common owing to acquired resistance. To unravel BRAFi resistance mechanisms we have performed gene expression and mass spectrometry based proteome profiling of the sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Azimi, Alireza, Tuominen, Rainer, Costa Svedman, Fernanda, Caramuta, Stefano, Pernemalm, Maria, Frostvik Stolt, Marianne, Kanter, Lena, Kharaziha, Pedram, Lehtiö, Janne, Hertzman Johansson, Carolina, Höiom, Veronica, Hansson, Johan, Egyhazi Brage, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596587/
https://www.ncbi.nlm.nih.gov/pubmed/29048432
http://dx.doi.org/10.1038/cddis.2017.406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596587/
https://www.ncbi.nlm.nih.gov/pubmed/29048432
http://dx.doi.org/10.1038/cddis.2017.406

Ejemplares similares